In its therapeutic antibody collaborations, MorphoSys produces optimized human antibodies for its partners according to their specifications. MorphoSys generates and optimizes the antibodies, whereas the partner is responsible for pre-clinical and clinical development.
Currently, MorphoSys’s partnered product pipeline comprises more than 60 antibody programs. MorphoSys’s list of partners includes a roster of blue-chip biotechnology and pharmaceutical firms, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co., Novartis, Pfizer and Roche.
Indications of Partnered Programs
Within these partnerships, MorphoSys develops antibodies for the treatment of diseases such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.
